|
Neonatal Intensive Care Drug Manual
|
| bet | 132/654 | | Sana | 03.01.2022 | | Hajmi | 1,5 Mb. | | #14803 |
Curosurf: Poractant alfa
Revision Date : 15-12-2020
|
Approved : TC, KOH
|
Alert
|
This medication should only be administered by a medical officer or nurse practitioner.
|
Indication
|
Treatment and prophylaxis of respiratory distress syndrome (RDS).
Treatment of meconium aspiration syndrome (MAS).
|
Action
|
Lowers surface tension on alveolar surfaces during respiration and stabilises the alveoli against collapse at resting trans pulmonary pressures.
|
Drug type
|
Pulmonary surfactant
|
Trade name
|
Curosurf
|
Presentation
|
Suspension for intra-tracheal use 120mg/1.5mL or 240mg/3mL vials
|
Dose
|
Respiratory distress syndrome
Loading dose of 200mg/kg
Repeat dose of 100mg/kg when required every 6–12 hours.
Maximum of 3 doses.
Meconium aspiration syndrome
Single dose: 200mg/kg
Further doses can be given as below if required:
2nd dose: 200mg/kg
3rd dose: 100mg/kg
4th dose: 100mg/kg
These doses can be administered at 6 hour interval.
|
Dose adjustment
|
Therapeutic hypothermia – Not applicable.
ECMO – Not applicable
Renal impairment – No dose adjustment.
Hepatic impairment – No dose adjustment.
|
Maximum dose
|
|
Total cumulative dose
|
|
Route
|
Intra-tracheal
|
Preparation
|
Not applicable
|
Administration
|
This medication should only be administered by a medical officer or nurse practitioner.
Inspect product visually for discolouration prior to administration (suspension should be white to creamy white). Before use, the vial should be slowly warmed to room temperature (can be warmed in hand or stood at room temperature) and gently turned upside down in order to obtain a uniform suspension. DO NOT SHAKE.
Poractant alpha is administered via the endotracheal route using an endotracheal tube (ETT) or thin catheter.
|
|
| |
